PGNX-PRICE TARGET $40, WHO
Company has $66.4M in cash or $5.5 per share with
almost no liabilities. Company is continuing with its
projects and as biopharmaceutical company has huge
potential. They have resources to continue with the
development until completion. Looks like on friday it was
overreaction. right now traders are trying to buy shares from
weak hands (still exist) at atractive prices, but soon
more and more investors will understand that company
worth mucu more than $10 per share.